Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > Goldman Sachs : C$42 target
View:
Post by Ellesse on Jun 07, 2016 8:37am

Goldman Sachs : C$42 target

CXR.TO : starts with neutral rating and C$42 target
Comment by marcrobert on Jun 07, 2016 9:29am
That's good news! Means they are interested, probably in banking fees related to the sale. Will put the name on more radar screens, although some will want to wait a year to see how healthcare shakes out after the election.
Comment by DrugPusher on Jun 07, 2016 9:36am
This post has been removed in accordance with Community Policy
Comment by select1011 on Jun 07, 2016 10:07am
This post has been removed in accordance with Community Policy
Comment by OscarTheGrouch on Jun 07, 2016 10:24am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities